Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 17 entries
Sorted by: Best Match Show Resources per page
alpha-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies.

International journal of oncology

Caraglia M, Leardi A, Ricciardi B, Delaurentiis M, Graziano M, Matano E, Deplacido S, Bianco A, Tagliaferri P.
PMID: 21544436
Int J Oncol. 1996 May;8(5):847-50. doi: 10.3892/ijo.8.5.847.

We have demonstrated that interferon-alpha 2 recombinant (IFN alpha) inhibits the growth and modulates the expression of the receptor for transferrin (TRF-R) in human epidermoid carcinoma KB cells. Receptor upregulation results in the reconstitution of intracellular iron levels in...

Cite
Caraglia M, Leardi A, Ricciardi B, et al. alpha-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies. Int J Oncol. 1996;8(5):847-50doi: 10.3892/ijo.8.5.847.
Caraglia, M., Leardi, A., Ricciardi, B., Delaurentiis, M., Graziano, M., Matano, E., Deplacido, S., Bianco, A., & Tagliaferri, P. (1996). alpha-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies. International journal of oncology, 8(5), 847-50. https://doi.org/10.3892/ijo.8.5.847
Caraglia, M, et al. "alpha-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies." International journal of oncology vol. 8,5 (1996): 847-50. doi: https://doi.org/10.3892/ijo.8.5.847
Caraglia M, Leardi A, Ricciardi B, Delaurentiis M, Graziano M, Matano E, Deplacido S, Bianco A, Tagliaferri P. alpha-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies. Int J Oncol. 1996 May;8(5):847-50. doi: 10.3892/ijo.8.5.847. PMID: 21544436.
Copy Download .nbib Format: NLM
Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Lim SG, Yang WL, Ngu JH, Chang J, Tan J, Ahmed T, Dan YY, Lim K, Lee YM, Lee GH, Tan PS, Wai KL, Phyo WW, Khine HHTW, Lee C, Tay A, Chan E.
PMID: 33895361
Clin Gastroenterol Hepatol. 2021 Apr 22; doi: 10.1016/j.cgh.2021.04.031. Epub 2021 Apr 22.

BACKGROUND & AIMS: The optimal therapeutic strategy in nucleoside analogue (NA) experienced chronic hepatitis B (CHB) using peginterferon is still unclear; hence we explored a switch to or add-on peginterferon strategy versus continued NA.METHODS: We conducted a randomized controlled...

Cite
Lim SG, Yang WL, Ngu JH, et al. Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT. Clin Gastroenterol Hepatol. 2021;doi: 10.1016/j.cgh.2021.04.031.
Lim, S. G., Yang, W. L., Ngu, J. H., Chang, J., Tan, J., Ahmed, T., Dan, Y. Y., Lim, K., Lee, Y. M., Lee, G. H., Tan, P. S., Wai, K. L., Phyo, W. W., Khine, H. H. T. W., Lee, C., Tay, A., & Chan, E. (2021). Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, . https://doi.org/10.1016/j.cgh.2021.04.031
Lim, Seng Gee, et al. "Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. (2021). doi: https://doi.org/10.1016/j.cgh.2021.04.031
Lim SG, Yang WL, Ngu JH, Chang J, Tan J, Ahmed T, Dan YY, Lim K, Lee YM, Lee GH, Tan PS, Wai KL, Phyo WW, Khine HHTW, Lee C, Tay A, Chan E. Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT. Clin Gastroenterol Hepatol. 2021 Apr 22; doi: 10.1016/j.cgh.2021.04.031. Epub 2021 Apr 22. PMID: 33895361.
Copy Download .nbib Format: NLM
The effect of education on quality of life in patients under interferon therapy.

Hepatitis monthly

Asadi Noghabi AA, Zandi M, Mehran A, Alavian SM, Dehkordi AH.
PMID: 22308142
Hepat Mon. 2010;10(3):218-22. Epub 2010 Sep 01.

BACKGROUND AND AIMS: The main purpose of treating and caring for patients with chronic viral hepatitis is to promote life satisfaction and a feeling of well-being in patients suffering from this disease. The aim of this study was to...

Cite
Asadi Noghabi AA, Zandi M, Mehran A, et al. The effect of education on quality of life in patients under interferon therapy. Hepat Mon. 2010;10(3):218-22
Asadi Noghabi, A. A., Zandi, M., Mehran, A., Alavian, S. M., & Dehkordi, A. H. (2010). The effect of education on quality of life in patients under interferon therapy. Hepatitis monthly, 10(3), 218-22.
Asadi Noghabi, Ahmad Ali, et al. "The effect of education on quality of life in patients under interferon therapy." Hepatitis monthly vol. 10,3 (2010): 218-22.
Asadi Noghabi AA, Zandi M, Mehran A, Alavian SM, Dehkordi AH. The effect of education on quality of life in patients under interferon therapy. Hepat Mon. 2010;10(3):218-22. Epub 2010 Sep 01. PMID: 22308142; PMCID: PMC3269087.
Copy Download .nbib Format: NLM
Peoscopic diagnosis of flat condyloma and penile intraepithelial neoplasia V scrotal reservoir.

Oncology reports

Relakis K, Cardamakis E, Kotoulas I, Stathopoulos E, Korantzis A, Metalinos K, Mantouvalos H, Tzingounis V, Koumantakis E.
PMID: 21594464
Oncol Rep. 1996 Sep;3(5):839-41. doi: 10.3892/or.3.5.839.

The aim of the present study was to evaluate prospectively male sexual partners of women with flat condyloma (FC) or accuminata (CA) or cervical intraepithelial neoplasia (CIN) and to determine the incidence of scrotal involvement by HPV. Of the...

Cite
Relakis K, Cardamakis E, Kotoulas I, et al. Peoscopic diagnosis of flat condyloma and penile intraepithelial neoplasia V scrotal reservoir. Oncol Rep. 1996;3(5):839-41doi: 10.3892/or.3.5.839.
Relakis, K., Cardamakis, E., Kotoulas, I., Stathopoulos, E., Korantzis, A., Metalinos, K., Mantouvalos, H., Tzingounis, V., & Koumantakis, E. (1996). Peoscopic diagnosis of flat condyloma and penile intraepithelial neoplasia V scrotal reservoir. Oncology reports, 3(5), 839-41. https://doi.org/10.3892/or.3.5.839
Relakis, K, et al. "Peoscopic diagnosis of flat condyloma and penile intraepithelial neoplasia V scrotal reservoir." Oncology reports vol. 3,5 (1996): 839-41. doi: https://doi.org/10.3892/or.3.5.839
Relakis K, Cardamakis E, Kotoulas I, Stathopoulos E, Korantzis A, Metalinos K, Mantouvalos H, Tzingounis V, Koumantakis E. Peoscopic diagnosis of flat condyloma and penile intraepithelial neoplasia V scrotal reservoir. Oncol Rep. 1996 Sep;3(5):839-41. doi: 10.3892/or.3.5.839. PMID: 21594464.
Copy Download .nbib Format: NLM
[Endocavitary prophylaxis of superficial urothelial bladder tumours: new compounds].

Urologia

Bartoletti R, Cai T.
PMID: 21086323
Urologia. 2009 Jan-Mar;76(1):1-9.

Bladder urothelial carcinoma is the fourth most frequent cancer among European men, accounting for about 7% of the total cancers. Transurethral resection (TUR) is usually indicated as the standard treatment for non-muscle invasive bladder cancer (NMIBC). However, TUR is...

Cite
Bartoletti R, Cai T. [Endocavitary prophylaxis of superficial urothelial bladder tumours: new compounds]. Urologia. 2009;76(1):1-9
Bartoletti, R., & Cai, T. (2009). [Endocavitary prophylaxis of superficial urothelial bladder tumours: new compounds]. Urologia, 76(1), 1-9.
Bartoletti, R, and Cai, T. "[Endocavitary prophylaxis of superficial urothelial bladder tumours: new compounds]." Urologia vol. 76,1 (2009): 1-9.
Bartoletti R, Cai T. [Endocavitary prophylaxis of superficial urothelial bladder tumours: new compounds]. Urologia. 2009 Jan-Mar;76(1):1-9. Italian. PMID: 21086323.
Copy Download .nbib Format: NLM
Heart failure induced by non-cardiac drugs.

Drug safety

Slørdal L, Spigset O.
PMID: 16808550
Drug Saf. 2006;29(7):567-86. doi: 10.2165/00002018-200629070-00003.

Although heart failure is predominantly caused by cardiovascular conditions such as hypertension, coronary heart disease and valvular heart disease, it can also be an adverse reaction induced by drug therapy. In addition, some drugs have the propensity to adversely...

Cite
Slørdal L, Spigset O. Heart failure induced by non-cardiac drugs. Drug Saf. 2006;29(7):567-86doi: 10.2165/00002018-200629070-00003.
Slørdal, L., & Spigset, O. (2006). Heart failure induced by non-cardiac drugs. Drug safety, 29(7), 567-86. https://doi.org/10.2165/00002018-200629070-00003
Slørdal, Lars, and Spigset, Olav. "Heart failure induced by non-cardiac drugs." Drug safety vol. 29,7 (2006): 567-86. doi: https://doi.org/10.2165/00002018-200629070-00003
Slørdal L, Spigset O. Heart failure induced by non-cardiac drugs. Drug Saf. 2006;29(7):567-86. doi: 10.2165/00002018-200629070-00003. PMID: 16808550.
Copy Download .nbib Format: NLM
Design, Expression, Purification, and Characterization of a YFP-Tagged 2019-nCoV Spike Receptor-Binding Domain Construct.

Frontiers in bioengineering and biotechnology

Bierig T, Collu G, Blanc A, Poghosyan E, Benoit RM.
PMID: 33409271
Front Bioeng Biotechnol. 2020 Dec 21;8:618615. doi: 10.3389/fbioe.2020.618615. eCollection 2020.

2019-nCoV is the causative agent of the serious, still ongoing, worldwide coronavirus disease (COVID-19) pandemic. High quality recombinant virus proteins are required for research related to the development of vaccines and improved assays, and to the general understanding of...

Cite
Bierig T, Collu G, Blanc A, et al. Design, Expression, Purification, and Characterization of a YFP-Tagged 2019-nCoV Spike Receptor-Binding Domain Construct. Front Bioeng Biotechnol. 2020;8:618615doi: 10.3389/fbioe.2020.618615.
Bierig, T., Collu, G., Blanc, A., Poghosyan, E., & Benoit, R. M. (2020). Design, Expression, Purification, and Characterization of a YFP-Tagged 2019-nCoV Spike Receptor-Binding Domain Construct. Frontiers in bioengineering and biotechnology, 8618615. https://doi.org/10.3389/fbioe.2020.618615
Bierig, Tobias, et al. "Design, Expression, Purification, and Characterization of a YFP-Tagged 2019-nCoV Spike Receptor-Binding Domain Construct." Frontiers in bioengineering and biotechnology vol. 8 (2020): 618615. doi: https://doi.org/10.3389/fbioe.2020.618615
Bierig T, Collu G, Blanc A, Poghosyan E, Benoit RM. Design, Expression, Purification, and Characterization of a YFP-Tagged 2019-nCoV Spike Receptor-Binding Domain Construct. Front Bioeng Biotechnol. 2020 Dec 21;8:618615. doi: 10.3389/fbioe.2020.618615. eCollection 2020. PMID: 33409271; PMCID: PMC7779597.
Copy Download .nbib Format: NLM
Host inflammatory response in women with vaginal epithelial abnormalities after pessary use.

International urogynecology journal

Ramaseshan AS, Mellen C, O'Sullivan DM, Nold C, Tulikangas PK.
PMID: 34748034
Int Urogynecol J. 2021 Nov 08; doi: 10.1007/s00192-021-05001-8. Epub 2021 Nov 08.

BACKGROUND: Vaginal epithelial abnormalities (VEA) are a common complication associated with pessary use. The objective of this study was to determine if there is a host pro-inflammatory response associated with pessary use and VEA.METHODS: Patients wearing pessaries for at...

Cite
Ramaseshan AS, Mellen C, O'Sullivan DM, et al. Host inflammatory response in women with vaginal epithelial abnormalities after pessary use. Int Urogynecol J. 2021;doi: 10.1007/s00192-021-05001-8.
Ramaseshan, A. S., Mellen, C., O'Sullivan, D. M., Nold, C., & Tulikangas, P. K. (2021). Host inflammatory response in women with vaginal epithelial abnormalities after pessary use. International urogynecology journal, . https://doi.org/10.1007/s00192-021-05001-8
Ramaseshan, Aparna S, et al. "Host inflammatory response in women with vaginal epithelial abnormalities after pessary use." International urogynecology journal vol. (2021). doi: https://doi.org/10.1007/s00192-021-05001-8
Ramaseshan AS, Mellen C, O'Sullivan DM, Nold C, Tulikangas PK. Host inflammatory response in women with vaginal epithelial abnormalities after pessary use. Int Urogynecol J. 2021 Nov 08; doi: 10.1007/s00192-021-05001-8. Epub 2021 Nov 08. PMID: 34748034.
Copy Download .nbib Format: NLM
Interferon-Alpha 2-a and Its Dual Effect in Treating Two Diseases (Hepatitis C and Polycythemia Vera).

Case reports in oncology

Shwaylia H, Ali E, Yassin MA.
PMID: 34248550
Case Rep Oncol. 2021 Jun 11;14(2):851-854. doi: 10.1159/000515782. eCollection 2021.

Hepatitis C and polycythemia vera (PV) co-existence is not rare; it has been reported in the literature. Treatment with interferon (IFN) has been used to treat both conditions; however, the use of IFN in concomitant hepatitis C infection with...

Cite
Shwaylia H, Ali E, Yassin MA. Interferon-Alpha 2-a and Its Dual Effect in Treating Two Diseases (Hepatitis C and Polycythemia Vera). Case Rep Oncol. 2021;14(2):851-854doi: 10.1159/000515782.
Shwaylia, H., Ali, E., & Yassin, M. A. (2021). Interferon-Alpha 2-a and Its Dual Effect in Treating Two Diseases (Hepatitis C and Polycythemia Vera). Case reports in oncology, 14(2), 851-854. https://doi.org/10.1159/000515782
Shwaylia, Hawraa, et al. "Interferon-Alpha 2-a and Its Dual Effect in Treating Two Diseases (Hepatitis C and Polycythemia Vera)." Case reports in oncology vol. 14,2 (2021): 851-854. doi: https://doi.org/10.1159/000515782
Shwaylia H, Ali E, Yassin MA. Interferon-Alpha 2-a and Its Dual Effect in Treating Two Diseases (Hepatitis C and Polycythemia Vera). Case Rep Oncol. 2021 Jun 11;14(2):851-854. doi: 10.1159/000515782. eCollection 2021. PMID: 34248550; PMCID: PMC8255747.
Copy Download .nbib Format: NLM
Treatment of flat or accuminata condylomata of the female genital tract with interferon alpha-2 alpha.

Oncology reports

Relakis K, Cardamakis E, Korantzis A, Kotoulas I, Stathopoulos E, Metalinos K, Papathanasiou Z, Mantouvalos H, Tzingounis V, Koumantakis E.
PMID: 21594489
Oncol Rep. 1996 Sep;3(5):951-5. doi: 10.3892/or.3.5.951.

This study was undertaken to assess the effectiveness of Interferon administered parenterally in the treatment of flat or accuminata condylomata of the female genital tract. One hundred and forty-three women with condylomata were treated with CO2 laser vaporization, 5-FU...

Cite
Relakis K, Cardamakis E, Korantzis A, et al. Treatment of flat or accuminata condylomata of the female genital tract with interferon alpha-2 alpha. Oncol Rep. 1996;3(5):951-5doi: 10.3892/or.3.5.951.
Relakis, K., Cardamakis, E., Korantzis, A., Kotoulas, I., Stathopoulos, E., Metalinos, K., Papathanasiou, Z., Mantouvalos, H., Tzingounis, V., & Koumantakis, E. (1996). Treatment of flat or accuminata condylomata of the female genital tract with interferon alpha-2 alpha. Oncology reports, 3(5), 951-5. https://doi.org/10.3892/or.3.5.951
Relakis, K, et al. "Treatment of flat or accuminata condylomata of the female genital tract with interferon alpha-2 alpha." Oncology reports vol. 3,5 (1996): 951-5. doi: https://doi.org/10.3892/or.3.5.951
Relakis K, Cardamakis E, Korantzis A, Kotoulas I, Stathopoulos E, Metalinos K, Papathanasiou Z, Mantouvalos H, Tzingounis V, Koumantakis E. Treatment of flat or accuminata condylomata of the female genital tract with interferon alpha-2 alpha. Oncol Rep. 1996 Sep;3(5):951-5. doi: 10.3892/or.3.5.951. PMID: 21594489.
Copy Download .nbib Format: NLM
Interleukin-2 and interferon alpha 2 combination.

Oncology reports

Pronzato P, Vigani A, Vaira F, Tani F, Vanoli M.
PMID: 21594525
Oncol Rep. 1996 Nov;3(6):1137-9. doi: 10.3892/or.3.6.1137.

We have studied activity and toxicity of subcutaneous recombinant interleukin-2 and interferon alpha 2b in a series of 14 patients with advanced renal cell carcinoma. No objective response was observed, and the median survival was 16 months (range 3-19);...

Cite
Pronzato P, Vigani A, Vaira F, et al. Interleukin-2 and interferon alpha 2 combination. Oncol Rep. 1996;3(6):1137-9doi: 10.3892/or.3.6.1137.
Pronzato, P., Vigani, A., Vaira, F., Tani, F., & Vanoli, M. (1996). Interleukin-2 and interferon alpha 2 combination. Oncology reports, 3(6), 1137-9. https://doi.org/10.3892/or.3.6.1137
Pronzato, P, et al. "Interleukin-2 and interferon alpha 2 combination." Oncology reports vol. 3,6 (1996): 1137-9. doi: https://doi.org/10.3892/or.3.6.1137
Pronzato P, Vigani A, Vaira F, Tani F, Vanoli M. Interleukin-2 and interferon alpha 2 combination. Oncol Rep. 1996 Nov;3(6):1137-9. doi: 10.3892/or.3.6.1137. PMID: 21594525.
Copy Download .nbib Format: NLM
Melanoma m (zero): diagnosis and therapy.

ISRN dermatology

Rastrelli M, Alaibac M, Stramare R, Chiarion Sileni V, Montesco MC, Vecchiato A, Campana LG, Rossi CR.
PMID: 23691346
ISRN Dermatol. 2013 Apr 11;2013:616170. doi: 10.1155/2013/616170. Print 2013.

This paper reviews the epidemiology, diagnosis, and treatment of M zero cutaneous melanoma including the most recent developments. This review also examined the main risk factors for melanoma. Tumor thickness measured according to Breslow, mitotic rate, ulceration, and growth...

Cite
Rastrelli M, Alaibac M, Stramare R, et al. Melanoma m (zero): diagnosis and therapy. ISRN Dermatol. 2013;2013:616170doi: 10.1155/2013/616170.
Rastrelli, M., Alaibac, M., Stramare, R., Chiarion Sileni, V., Montesco, M. C., Vecchiato, A., Campana, L. G., & Rossi, C. R. (2013). Melanoma m (zero): diagnosis and therapy. ISRN dermatology, 2013616170. https://doi.org/10.1155/2013/616170
Rastrelli, Marco, et al. "Melanoma m (zero): diagnosis and therapy." ISRN dermatology vol. 2013 (2013): 616170. doi: https://doi.org/10.1155/2013/616170
Rastrelli M, Alaibac M, Stramare R, Chiarion Sileni V, Montesco MC, Vecchiato A, Campana LG, Rossi CR. Melanoma m (zero): diagnosis and therapy. ISRN Dermatol. 2013 Apr 11;2013:616170. doi: 10.1155/2013/616170. Print 2013. PMID: 23691346; PMCID: PMC3649440.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 17 entries